Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Significant Expenses

In addition to the significant expense categories included within consolidated net income presented on the Company's Condensed Consolidated Statements of Operations, see below for disaggregated amounts that comprise research and development expenses:

	Three Months Ended September 30,				Nine Months Ended September 30,
(In millions)	2025		2024		2025		2024
Direct research and development expenses(a)	$	454.3	$	386.4	$	1,296.7	$	1,158.5
Indirect research and development expenses:
Payroll and benefits	438.3		407.8		1,339.5		1,249.2
Lab supplies and other research and development costs	67.5		63.0		192.4		175.4
Occupancy and other operating costs	166.3		158.7		479.2		434.9
Total indirect research and development expenses	672.1		629.5		2,011.1		1,859.5
Clinical manufacturing costs	381.4		306.6		1,028.8		841.3
Reimbursement of research and development expenses by collaborators	(32.8)		(51.0)		(112.5)		(139.4)
Total research and development expenses	$	1,475.0	$	1,271.5	$	4,224.1	$	3,719.9
(a) Direct research and development expenses are comprised primarily of costs paid to third parties for clinical and product development activities, and the portion of research and development expenses incurred by our collaborators that we are obligated to reimburse